ClinicalTrials.gg
CompletedNCT07147257Updated Jan 28, 2026Results posted

A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions

A Phase 1 interventional study of CHS-1420 and HUMIRA® in Healthy Participants, sponsored by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Feb 2025, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
238
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A Single-Center, Randomized, Single-Blind, Single-Dose, Parallel-Group Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants under Fasting Conditions

02

Conditions studied

  • Healthy Participants

Keywords

  • Adalimumab
  • Pharmacokinetic
03

In context

Lead sponsor

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide signed Form before the trial, and fully understand the trial content, process and possible adverse drug reactions (ADRs)
  2. Able to complete the trial in compliance with the protocol
  3. Participants (including males) willing to adopt effective methods and with no pregnancy plan from 14 days before screening to 6 months after the last scheduled visit
  4. Males and females between 18 and 55 years old, inclusive
  5. At least 50 kg for participants, with a (BMI)=Weight/ Height2 (kg/m2) between 19.0-26.0 kg/m2, inclusive
  6. No history of chro nic or serious cardiac, hepatic, renal, digestive tract,nervous system, hematologic, respiratory, dermatological, mental and metabolic disorders, etc.

Exclusion criteria

Exclusion Criteria:

  1. With ≥ 5 cigarettes per day on average within 3 months before screening, or not able to quit smoking during the trial
  2. Allergic constitution, or allergic to the drug components and its analogues; history of allergic reaction to a biological medication
  3. A history of alcohol abuse (alcohol consumption of more than 14 units per week : 1 unit of alcohol = 285 mL beer, or 25 mL spirits, or 100 mL wine)
  4. Blood donation or massive blood loss (> 400 mL) within 3 months before products dosing; Or any blood donation plan from screening until 3 months after administration
  5. History of any major surgery within the past year, or history of any surgery within the past 6 months; or any elective medical procedures, including dental procedures
  6. Any history of organ transplantation
  7. Medical history of tuberculosis (or suspected tuberculosis), or with a positive tuberculosis test result
  8. Medical history of heart failure or other cardiac disorders which may lead to heart failure, e.g. coronary heart disease, hypertension, senile degenerative valvular disease, rheumatic valvular heart disease, dilated cardiomyopathy, acute severe myocarditis
  9. Medical history of immune system disorders (e.g. systemic lupus erythematosus, multiple sclerosis, etc.), or positive results of antinuclear antibody tests
  10. Medical history of recurrent or chronic infections (including transverse myelitis, optic neuritis, other demyelinating disorders, etc.), or a history of an opportunistic infection within the past year due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens
  11. History of seizure attack
  12. Medication history of TNF-α blockers e.g. Adalimumab or its analogues
  13. Any medication of monoclonal antibodies within the past year before investigational products dosing
  14. Any usage history of prescription medicines or OTCs (especially antibiotics), or Chinese herbal medicine or health supplementary within 30 days before investigational products dosing
  15. Any vaccination within 3 months before investigational products dosing, or any plan for vaccination within 3 months after investigational products administration
  16. Consumption of any special diets or food items (such as grapefruit), or strenuous exercise engagement, or other factors in the opinion of investigators affecting drug absorption, distribution, metabolism and excretion within 7 days before investigational products dosing
  17. Participation in other drug clinical trials within 3 months before investigational products dosing
  18. Any abnormality findings, as judged by a clinical physican, such as physical examination, vital signs, and laboratory tests, as well as Chest X-ray
  19. Positive results of surface antigen, antibody, and antibody or syphilis
  20. Consumption of chocolate or any food/beverage containing caffeine or rich in xanthine within 48 h before investigational products dosing
  21. Consumption of any products containing alcohol within 48 h before investigational products dosing, or a positive result of the alcohol breath test
  22. A positive result of the drug abuse test, or a history of drug abuse in the past 5 years, or intake of any narcotic drugs within 3 months prior to the trial
  23. A positive result of the pregnancy test, or in lactation during screening or the test period for female participants
  24. Not tolerable on venipuncture, or a history of fainting on acupuncture and/or blood
  25. Special requirements and unable to follow the unified diet
  26. Unable to participate in this trial for participants' own reasons
  27. Other conditions in which participants are not suitable for the trial determined by investigators
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
238 participants (actual)

Study arms

  • Experimental
    CHS-1420

    Biological: CHS-1420

  • Active comparator
    HUMIRA®

    Biological: HUMIRA®

Interventions

  • BiologicalCHS-1420

    Dose of 40 mg will be subcutaneously administered to participants in

  • BiologicalHUMIRA®

    Dose of 40 mg will be subcutaneously administered to participants in

06

What researchers measure

Primary outcomes

  1. Areas Under the Serum Concentration Versus Time Curve Extrapolated to Infinity (AUC0-∞)

    pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

    Time frame: 0 to 1536 hours post-dose

  2. The Maximum Serum Drug Concentration (Cmax)

    pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

    Time frame: 0 to 1536 hours post-dose

Secondary outcomes

  1. Areas Under the Serum Concentration Versus Time Curve Calculated to the Last Measurable Observation (AUC0-t)

    pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

    Time frame: 0 to 1536 hours post-dose

  2. Areas Under the Serum Concentration Versus Time Curve Calculated to 65 Days Postdose(AUC0-65days)

    pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

    Time frame: 0 to 1536 hours post-dose

  3. The Time to Maximum Serum Concentration(Tmax)

    pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

    Time frame: 0 to 1536 hours post-dose

  4. The Elimination Half-life (t1/2)

    pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

    Time frame: 0 to 1536 hours post-dose

  5. Elimination Rate Constant (Kel)

    pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

    Time frame: 0 to 1536 hours post-dose

  6. Volumeof Distribution (Vd/F)

    pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

    Time frame: 0 to 1536 hours post-dose

  7. Clearance(CL/F)

    pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

    Time frame: 0 to 1536 hours post-dose

  8. Immunogenicity Estimands

    Presence of anti-adalimumab antibodies

    Time frame: Day1 to Day 65

  9. Safety Estimands

    Frequency of Adverse Events

    Time frame: Day1 to Day 65

07

Results

Posted Jan 9, 2026

Participant flow

Participant flow — Overall Study
MilestoneCHS-1420HUMIRA®
Started119119
Completed118116
Not completed13
Withdrew: Pregnancy10
Withdrew: Physician decision01
Withdrew: Withdrawal by subject01
Withdrew: Drug administration failure01

Outcome measures

PrimaryAreas Under the Serum Concentration Versus Time Curve Extrapolated to Infinity (AUC0-∞)

pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

Time frame:
0 to 1536 hours post-dose
Reported as:
Mean · h*ng/mL
Areas Under the Serum Concentration Versus Time Curve Extrapolated to Infinity (AUC0-∞)
h*ng/mLCHS-1420HUMIRA®
Areas Under the Serum Concentration Versus Time Curve Extrapolated to Infinity (AUC0-∞)2321566.8 ± 995890.412358855.5 ± 1038026.70
PrimaryThe Maximum Serum Drug Concentration (Cmax)

pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

Time frame:
0 to 1536 hours post-dose
Reported as:
Mean · ng/mL
The Maximum Serum Drug Concentration (Cmax)
ng/mLCHS-1420HUMIRA®
The Maximum Serum Drug Concentration (Cmax)3602.38 ± 1145.9633620.75 ± 1489.729
SecondaryAreas Under the Serum Concentration Versus Time Curve Calculated to the Last Measurable Observation (AUC0-t)

pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

Time frame:
0 to 1536 hours post-dose
Reported as:
Mean · h*ng/mL
Areas Under the Serum Concentration Versus Time Curve Calculated to the Last Measurable Observation (AUC0-t)
h*ng/mLCHS-1420HUMIRA®
Areas Under the Serum Concentration Versus Time Curve Calculated to the Last Measurable Observation (AUC0-t)2153350.8 ± 808597.632191368.0 ± 884277.79
SecondaryAreas Under the Serum Concentration Versus Time Curve Calculated to 65 Days Postdose(AUC0-65days)

pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

Time frame:
0 to 1536 hours post-dose
Reported as:
Mean · h*ng/mL
Areas Under the Serum Concentration Versus Time Curve Calculated to 65 Days Postdose(AUC0-65days)
h*ng/mLCHS-1420HUMIRA®
Areas Under the Serum Concentration Versus Time Curve Calculated to 65 Days Postdose(AUC0-65days)2154968.6 ± 807292.732192846.0 ± 883361.98
SecondaryThe Time to Maximum Serum Concentration(Tmax)

pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

Time frame:
0 to 1536 hours post-dose
Reported as:
Median · h
The Time to Maximum Serum Concentration(Tmax)
hCHS-1420HUMIRA®
The Time to Maximum Serum Concentration(Tmax)168.000 (36.00 to 528.00)156.000 (12.00 to 360.02)
SecondaryThe Elimination Half-life (t1/2)

pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

Time frame:
0 to 1536 hours post-dose
Reported as:
Mean · h
The Elimination Half-life (t1/2)
hCHS-1420HUMIRA®
The Elimination Half-life (t1/2)240.698 ± 219.3439238.869 ± 186.2289
SecondaryElimination Rate Constant (Kel)

pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

Time frame:
0 to 1536 hours post-dose
Reported as:
Mean · 1/h
Elimination Rate Constant (Kel)
1/hCHS-1420HUMIRA®
Elimination Rate Constant (Kel)0.0053 ± 0.00340.0050 ± 0.0034
SecondaryVolumeof Distribution (Vd/F)

pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

Time frame:
0 to 1536 hours post-dose
Reported as:
Mean · mL
Volumeof Distribution (Vd/F)
mLCHS-1420HUMIRA®
Volumeof Distribution (Vd/F)5489.1 ± 3152.115687.4 ± 3240.04
SecondaryClearance(CL/F)

pre-dose (0 h) and at 2, 4, 8, 12,24,36,48,60,72,96,120,144,168,216,288,360,528,696,864,1032,1200,1368,1536h post-dose

Time frame:
0 to 1536 hours post-dose
Reported as:
Mean · mL/h
Clearance(CL/F)
mL/hCHS-1420HUMIRA®
Clearance(CL/F)20.6798 ± 8.880820.9731 ± 10.7637
SecondaryImmunogenicity Estimands

Presence of anti-adalimumab antibodies

Time frame:
Day1 to Day 65
Reported as:
Count of participants · Participants
Immunogenicity Estimands
ParticipantsCHS-1420HUMIRA®
ADA positive participants at 0h14
baseline negative ADA participants with at least one post dose positive ADA result109100
No Anit-Drug Antibody Confirmed Positive Results914
SecondarySafety Estimands

Frequency of Adverse Events

Time frame:
Day1 to Day 65
Reported as:
Count of participants · Participants
Safety Estimands
ParticipantsCHS-1420HUMIRA®
Safety Estimands5969

Adverse events

Collected over from enrollment until end of follow-up, up to 65 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CHS-14200/119 (0%)0/119 (0%)59/119 (49.6%)
HUMIRA®0/119 (0%)0/119 (0%)69/119 (58%)
Most frequent other events
Showing 10 of 38
Most frequent other events
EventCHS-1420HUMIRA®
Blood triglycerides increasedInvestigations23/11931/119
Neutrophil count decreasedInvestigations9/11910/119
Alanine aminotransferase increasedInvestigations9/1198/119
Lymphocyte count increasedInvestigations3/1197/119
Low density lipoprotein increasedInvestigations6/1192/119
White blood cells urine positiveInvestigations3/1195/119
White blood cell count decreasedInvestigations2/1195/119
Aspartate aminotransferase increasedInvestigations4/1194/119
LeukocytosisBlood and lymphatic system disorders3/1194/119
AnaemiaBlood and lymphatic system disorders2/1194/119

Baseline characteristics

All randomized participants

Age, Categorical
Age, Categorical(Participants)CHS-1420HUMIRA®Total
<=18 years000
Between 18 and 65 years119119238
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)CHS-1420HUMIRA®Total
Female444488
Male7575150
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CHS-1420HUMIRA®Total
American Indian or Alaska Native000
Asian119119238
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
BMI
BMI(kg/m^2)CHS-1420HUMIRA®Total
Mean23.33 ± 1.43723.25 ± 1.68923.29 ± 1.565
08

Study locations

1 site
  • Ethics Committee of Hopeshine-Minsheng Hospital of Xinzheng
    Zhengzhou, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in May 2025, 2 months.

Results were first posted in Jan 2026, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Aug 29, 2025
StartActual
Feb 12, 2025
Primary completionActual
May 6, 2025
CompletionActual
May 29, 2025
Results first posted
Jan 9, 2026
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07147257
Lead sponsor
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Aug 29, 2025
Start date
Feb 12, 2025
Primary completion
May 6, 2025
Completion
May 29, 2025
Results posted
Jan 9, 2026
Last update
Jan 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion